` THOXF (Bioporto A/S) vs S&P 500 Comparison - Alpha Spread

THOXF
vs
S&P 500

Over the past 12 months, THOXF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +16% growth.

Stocks Performance
THOXF vs S&P 500

Loading
THOXF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
THOXF vs S&P 500

Loading
THOXF
S&P 500
Difference
www.alphaspread.com

Performance By Year
THOXF vs S&P 500

Loading
THOXF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bioporto A/S vs Peers

S&P 500
THOXF
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bioporto A/S
Glance View

Market Cap
130.9m USD
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

THOXF Intrinsic Value
0.279 USD
Overvaluation 3%
Intrinsic Value
Price
Back to Top